Table 2 Characteristics of included studies

From: Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

       Dose classifications  
Study Year Medication Duration N Response Criteria Low (mg) Medium (mg) High (mg) Results
Montgomery 1993 Fluoxetine 8 weeks 214 25% Y-BOCS and CGI<3 20 40 60 HIGH=MEDIUM=LOW=PLACEBO
Tollefson 1994 Fluoxetine 13 weeks 355 CGI<3 20 40 60 HIGH=MEDIUM=LOW>PLACEBO
Greist 1995 Sertaline 12 weeks 325 CGI<3 50 100 200 HIGH=LOW>PLACEBO, MEDIUM not statistically different from other groups
Nakajima 1996 Fluvoxamine 8 weeks 131 CGI<3 150   300 HIGH=LOW>PLACEBO
Ushijima 1997 Sertaline 8 weeks 104 CGI<3   100 200 HIGH=MEDIUM>PLACEBO
Zitterl 1999 Fluoxetine 8 weeks 53 CGI<3 20 40 60 HIGH=MEDIUM>LOW=PLACEBO
Montgomery 2001 Citalopram 12 weeks 401 25% YBOCS 20 40 60 HIGH=MEDIUM=LOW>PLACEBO
Hollander 2003 Paroxetine 12 weeks 348   20 40 60 HIGH>LOW=PLACEBO, MEDIUM>PLACEBO but MEDIUM=HIGH, LOW
Stein 2007 Escitalopram 12 weeks 337 25% YBOCS 10 20   MEDIUM>PLACEBO, LOW not statistically different from other groups
  1. CGI, Clinical Global Impression.
  2. We found 9 studies involving 2268 OCD patients in randomized, double-blind, placebo-controlled, fixed-dose studies of selective serotonin reuptake inhibitors in OCD. The results in the right-most column indicate statistically significant differences between SSRI dose categories for individual studies using the Y-BOCS scale.